How many drugs treat Staphylococcal septicemia?

Drug Landscape tracks 10 marketed treatments for Staphylococcal septicemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Staphylococcal septicemia?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/staphylococcal-septicemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Staphylococcal septicemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Staphylococcal septicemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcal septicemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Methocillin S	CLOXACILLIN	GSK	cloxacillin		1974-01-01
Cleocin T	CLINDAMYCIN PHOSPHATE	Pfizer	Lincosamide Antibacterial		1972-01-01
Bactocill In Plastic Container	OXACILLIN	Apothecon		Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1971-01-01
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Vancocin	vancomycin	ANI Pharmaceuticals		Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

GSK · 2 drugs in Staphylococcal septicemia
Bristol-Myers Squibb · 2 drugs in Staphylococcal septicemia
Apothecon · 1 drug in Staphylococcal septicemia
Centre Hospitalier Universitaire Vaudois · 1 drug in Staphylococcal septicemia
Generic (originally Roche) · 1 drug in Staphylococcal septicemia
Generic (originally Upjohn/Pfizer) · 1 drug in Staphylococcal septicemia
· 1 drug in Staphylococcal septicemia
Pfizer · 1 drug in Staphylococcal septicemia
ANI Pharmaceuticals · 1 drug in Staphylococcal septicemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcal septicemia:

Cite this brief

Drug Landscape (2026). Staphylococcal septicemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcal-septicemia. Accessed 2026-06-10.

Staphylococcal septicemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing